智通财经APP讯，泰凌医药(01011)发布公告，于2026年2月9日，公司与认购人(杭州经纬生命科技有限公司、黄剑山先生)订立认购协议，据此，认购人已有条件同意认购，而本公司已有条件同意发行本金总额为6500万港元的2028年到期的两年期无抵押5%计息可换股债券。发行债券的所得款项总额及所得款项净额将分别约为6500万港元及6400万港元。公司拟将所得款项净额用于一般营运资金及偿还贷款。
于本公告日期，公司已发行股份合共6.74亿股。假设(i)公司的现有股权并无其他变动;(ii)认购协议项下的先决条件于最后截止日期或之前获达成;(iii)本金额为6500万港元的债券附带的所有换股权获认购人按换股价每股换股股份0.64港元悉数行使，则认购人将于1.016亿股股份中拥有权益，占公司于本公告日期的已发行股本约15.06%，及占公司经根据认购协议悉数行使债券项下换股权而配发及发行换股股份扩大后的已发行股本约13.09%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.